Navigation Links
Palatin Technologies and King Pharmaceuticals Announce Plan To,Present Results of Bremelanotide Phase 2b Studies in Men With,Erectile Dysfunction

CRANBURY, N.J. and BRISTOL, Tenn., May 09, 2007 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. and King Pharmaceuticals, Inc. today announced plans to present the results from two bremelanotide Phase 2b studies of men with erectile dysfunction (ED). The presenters are Jed Kaminetsky, MD, Clinical Assistant Professor, Department of Urology, NYU School of Medicine; Stanley E. Althof, PhD, Professor of Psychology, Case Western Reserve School of Medicine and Christopher Steidle, MD, Clinical Associate Professor of Urology, Indiana University School of Medicine.

The companies plan to present the results at the American Urological Association (AUA) Annual Meeting in Anaheim, CA, which takes place May 19-24, 2007. The Phase 2b studies were designed to evaluate the safety and efficacy of bremelanotide for the treatment of male ED using a range of intranasally administered doses in an at-home environment. A total of 726 and 294 patients were enrolled in a non-diabetic ED patient study and a diabetic ED patient study, respectively. Palatin and King announced initial positive results from the Phase 2b trial evaluating bremelanotide for the treatment of male non- diabetic ED patients in November 2006.

Dr. Kaminetsky's presentation, titled "Phase 2b Study of Bremelanotide in the Treatment of ED in Non-Diabetic Males," and Dr. Althof's presentation, titled "Improvement in Sexual Relationship Satisfaction, Confidence, and Self- Esteem in ED Patients Treated with Bremelanotide," will be presented at a podium session titled "Sexual Function/Dysfunction/Andrology: Evaluation (II)" on Monday, May 21st at 1:00 PM PDT. Dr. Steidle's poster, titled "Phase 2b Study of Bremelanotide in the Treatment of ED in Diabetic Males," will be presented at a poster session titled "Sexual Function/Dysfunction/Andrology: Surgical, Medical and Non-surgical Therapy (II)" from 3:30 PM - 5:30 PM PDT on Monday, May 21st.

Abou
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
2. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Genelabs Technologies Announces Presentation of Data on Non-Nucleoside HCV Polymerase Inhibitor at 20th International Conference on Antiviral Research Meeting
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:
(Date:11/9/2009)...CISCO, Calif., Nov. 9 An...on November 5, 2009, it received a letter from The...he Nasdaq Hearing Panel has granted Anesiva,s requ...ket subject to the condition that Anesiva shall ha...roposed merger (the "Merger") contemplated by the ...
(Date:11/7/2009)...la., Nov. 7 Patients reported C1-e...tive therapy in treating acute swelling attacks at...etic disorder, according to data presented today a...p; Immunology (ACAAI) Annual Meeting. The results ...cted in parallel with the ongoing, prospective, op...
(Date:11/6/2009)... WASHINGTON, Pa., Nov. 6 In consul...(FDA), McNeil Consumer Healthcare, Division of McN... a limited number of product lots of TYLENOL®... distinctive red EZ-OPEN CAP. McNeil is initiating...smell or taste associated with these lots that led...
Breaking Medicine Technology:Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 2Hereditary Angioedema Patients Report: C1-Esterase Inhibitor Concentrate Effective in Treating Acute Attacks, Helps Them Avoid Emergency Care 3McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 1Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 2Light Sciences Oncology Expands Development of Novel Targeted Drug Aptocine 28TM 29 For Prostate Conditions With Start Up of Phase 2 BPH Trial 54732 3Abnormal Protein May Signal Pancreatic Cancer 54730 1Abnormal Protein May Signal Pancreatic Cancer 54730 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 1Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 2Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development 9609 3
...th Lovenox(R) (enoxaparin sodium injection) were a...l within 90 days-, BRIDGEWATER, N.J., Dec 10 San... that demonstrated total hospital,direct medical c...$550 per,patient when they were treated with the u...actionated heparin (UFH) with 97.3% of LMWH patien...
... 10 Alfacell Corporation,(Nasdaq: ACEL ) today r...r,of fiscal 2008., The company recorded a net los...c and diluted common share, for the fiscal quarter...ion, or $0.05 per basic and diluted,common share, ...administrative expenses increased by approximately...
Other Medicine Technology:Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 2Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 3Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 4Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH) 5Alfacell Reports Financial Results for First Quarter of Fiscal 2008 2Alfacell Reports Financial Results for First Quarter of Fiscal 2008 3Alfacell Reports Financial Results for First Quarter of Fiscal 2008 4Alfacell Reports Financial Results for First Quarter of Fiscal 2008 5
(Date:11/9/2009)...N, Nov. 9 Today,s drama...gs us one step closer to meaningful health care re...th Care for America Act makes health care more acc...y enhancing coverage, promoting preventive care an...lso serves as a sober reminder of the tremendous a...
(Date:11/9/2009)... New Health Care Reform Bill, The Afford...he House Of Representatives Saturday Night, and Is...bama by the End of the Year with Absolute Confiden...alist Certification Class Specifically for the Com...% of Americans , Hanover ...
(Date:11/9/2009)... Only 5 percent of seniors have changed ...avings, better service and improved coverage among...llment season nears , , B...ly 5 percent of seniors have changed their Medicar...y (16 percent) report they are likely to or are co...
(Date:11/9/2009)...inds that women treated for breast cancer are at h... breasts. Published in the December 15, 2009 issue...can Cancer Society, the study,s results indicate t...benefit from additional therapies following surger...e that women with dense breast tissue are at incre...
(Date:11/8/2009)...HIA, Nov. 8 The America...evention and wellness provisions in the health ref...th passage of this bill, the House takes important...tant insurance reforms and moving our health syste...e that focuses on keeping people healthy," said Ge...
Breaking Medicine News(10 mins):Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 2Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 3Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 4Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 5Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Breast density associated with increased risk of cancer recurrence 2Health News:APHA Applauds Prevention and Wellness Provisions in House Health Reform Bill 2
...The U-C-L-A Medical Center, in Los Angeles is witn...on after a heart transplant. His twin, also in nee...// Nick and Nate Draper, the twin brothers wer...enter. According to the Doctors, Nick Draper...
... study led by Ronald Hines, professor of pediatric...ult and children have very different drug metaboli...s (enzymes) in their body for the processing of th...e young. This plays a vital role because certa...
...ior doctor has by the means of BMJ raised a seriou...alization purposes. // This has come after n... approved and thereafter recalled after three mont... Drug Administration in 2004 on the basis of short...
...ses like diabetes, cancer and heart attack that ar...s could cause much strain to the Indian economy, /...ost by 2015, according to estimates by World Healt...s Robert Beaglehole, director of NCD, WHO. H...
...us concerns have been raised regarding the safety ...ports of increased risk of autism // in children ...st mumps, measles and rubella. Currently, ch...nt vaccine preventable diseases. The government ha...
...ed River Valley Water Supply Project's key agenda ...stern North Dakota, especially heavily populated a...ronmental groups are up in arms against this propo...eels that a task of such a magnitude , interbasin ...
Other Medicine News:
Moody Curved Fixation Forceps
Lindstrom Curved Pierce Forcep
Green Fixation Forceps
Kuhnt Fixation Forceps
Medicine Products: